US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold : vimarsana.com

Mersana Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had paused enrollment in two studies of its ovarian cancer drug after five deaths in bleeding-related events, sending shares of the company tumbling.

Related Keywords

Bengaluru , Karnataka , India , Shinjini Ganguli , Khushi Mandowara , Savio Dsouza , Mersana Therapeutics Inc , Drug Administration , Reuters , Thomson Reuters Trust Principles , Therapeutics Inc , Mersana Therapeutics , Saviod Souza , Thomson Reuters Trust , Mersana , Therapeutics , Study , Bio Therapeutic Drugs Trbc Level 5 , Company News , Obstetric Gynaecological Conditions , Health Medicine , Volatile Shares Hot Stocks , Medical Regulation , Biotechnology Amp Medical Research Trbc Level 4 , North America , Pharmaceuticals Amp Medical Research Trbc Level 2 , United States ,